Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Search Results to Iris Romero

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following properties of Romero, Iris

PropertyValue
overview Dr. Romero is an Associate Professor in the Department of Obstetrics and Gynecology at the University of Chicago. Her research program focuses on identifying novel interventions for ovarian cancer prevention and treatment. To approach this her lab evaluates the cancer protective effects of medications that are widely used for non-cancer indications. Given the high cost and difficulty of new cancer drug development, drug repurposing or taping into the anti-carcinogenic potential of economical and widely used drugs is an important paradigm shift in cancer research. Her research program integrate of in vitro cancer biology techniques, mouse models of ovarian cancer and human clinical data and samples. Using this integrated approach, her group has reported anti-ovarian cancer effects of two commonly used medications: metformin used for diabetes and statins used for high cholesterol. Complementary to her research endeavors, Dr. Romero’s clinical practice provides comprehensive obstetrical and gynecological care to women at high risk for gynecologic malignancies, including those with a genetic predisposition to cancer.

One or more keywords matched the following items that are connected to Romero, Iris

Item TypeName
Concept Ovarian Neoplasms
Academic Article Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice.
Academic Article CD95 promotes tumour growth.
Academic Article Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.
Academic Article The effects of 17ß-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis.
Academic Article Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth.
Academic Article Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity.
Academic Article Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion.
Academic Article Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis.
Academic Article Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.
Academic Article Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer.
Academic Article Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
Academic Article Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers.
Academic Article Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention.
Academic Article SPHK1 Is a Novel Target of Metformin in Ovarian Cancer.
Academic Article A Pan-ALDH1A Inhibitor Induces Necroptosis in Ovarian Cancer Stem-like Cells.
Academic Article Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group.
Academic Article Mesothelial Cell HIF1a Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk.
Academic Article Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance.

Search Criteria
  • Ovarian Cancer